ETESEVIMAB

Course overview

THE FDA (FOOD AND DRUG ADMINISTRATION) HAS APPROVED THE COMBINATION PRODUCTS (ETESEVIMAB AND BAMLANIVIMAB) THROUGH EUA (EMERGENCY USE AUTHORIZATIONS). THIS ACTIVITY OUTLINES THE INDICATIONS, CONTRAINDICATIONS, AND PRECAUTIONS FOR USING ETESEVIMAB AS A VALUABLE AGENT IN THE MANAGEMENT OF MILD TO MODERATE SARS-COV-2 IN NONHOSPITALIZED OUTPATIENTS AT HIGH RISK FOR PROGRESSING TO SEVERE DISEASE. THIS ACTIVITY WILL ALSO HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, DOSING, AND MONITORING WHILE ADMINISTERING THE MEDICATIONS PERTINENT FOR THE HEALTHCARE TEAM MEMBERS TO MANAGE PATIENTS WITH MILD TO MODERATE SARS-COV-2.